{"id":{"repo_id":"ull","oai_identifier":"oai:riull.ull.es:915/100"},"canonical_url":"https://search.dev.ndltd.org/etd/ull/oai:riull.ull.es:915/100","repository":{"repo_id":"ull","name":"Universidad de la Laguna","base_url":"https://riull.ull.es/oai/request"},"display":{"title":"Análisis de dos esquemas de tratamiento con hierro oral e intravenoso en cirugía cardiaca : ensayo clínico en fase IV, randomizado, doble ciego y doble enmascarado","abstract":"Background: Anemia is a frequent complication after cardiopulmonary bypass surgery. Iron therapy has been variably employed by medical centres over the years. Objective: To test the clinical effectiveness of intravenous and oral iron supplementation in correcting anemia, and its impact on blood transfusion requirements, in patients undergoing cardiopulmonary bypass (CPB) surgery. Methods: A double-blind randomized placebo-controlled clinical trial with three parallel groups of patients. Group I (n=54): intravenous iron III-hydroxide sucrose complex, three doses of 100 mg /24 hours during pre- and postoperative hospitalization and 1 pill/24 h of oral placebo in the same period and during one month after discharge. Group II (n=53): oral ferrous fumarate iron 1 pill/24 hours pre- and postoperatively and during one month after discharge, and intravenous placebo while hospitalized. Group III (n=52): oral and intravenous placebo pre- and postoperatively, following the same protocol. Data were collected preoperatively, at theatre, at Intensive Care Unit admission, before hospital discharge and one month later. Results: 1) Baseline clinical and demographic characteristics and surgical procedures were similar in the three groups, 2) no inter-group differences were found in hemoglobin and hematocrit during the postoperative period, 3) the intravenous iron group showed higher serum ferritin levels at hospital discharge (1321±495 ng/mL; P<0.001) and one month later (610±387;P< 0.001) compared with the other groups, and 4) we did not observe statistical differences in blood transfusion requirements between the three groups. Conclusion: The use of intravenous or oral iron supplementation proved ineffective at correcting anemia after CPB and did not reduce blood transfusion requirements.","abstract_html":"Background: Anemia is a frequent complication after cardiopulmonary bypass surgery. Iron therapy has been variably employed by medical centres over the years. Objective: To test the clinical effectiveness of intravenous and oral iron supplementation in correcting anemia, and its impact on blood transfusion requirements, in patients undergoing cardiopulmonary bypass (CPB) surgery. Methods: A double-blind randomized placebo-controlled clinical trial with three parallel groups of patients. Group I (n=54): intravenous iron III-hydroxide sucrose complex, three doses of 100 mg /24 hours during pre- and postoperative hospitalization and 1 pill/24 h of oral placebo in the same period and during one month after discharge. Group II (n=53): oral ferrous fumarate iron 1 pill/24 hours pre- and postoperatively and during one month after discharge, and intravenous placebo while hospitalized. Group III (n=52): oral and intravenous placebo pre- and postoperatively, following the same protocol. Data were collected preoperatively, at theatre, at Intensive Care Unit admission, before hospital discharge and one month later. Results: 1) Baseline clinical and demographic characteristics and surgical procedures were similar in the three groups, 2) no inter-group differences were found in hemoglobin and hematocrit during the postoperative period, 3) the intravenous iron group showed higher serum ferritin levels at hospital discharge (1321±495 ng/mL; P&lt;0.001) and one month later (610±387;P&lt; 0.001) compared with the other groups, and 4) we did not observe statistical differences in blood transfusion requirements between the three groups. Conclusion: The use of intravenous or oral iron supplementation proved ineffective at correcting anemia after CPB and did not reduce blood transfusion requirements.","abstract_has_math":false,"creators":["Rodríguez Fortúnez, Patricia María"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014","date_published":"2014","updated_at":"2026-07-24T05:12:21Z","subjects":[],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["hdl:915/100"],"render_values":[{"text":"hdl:915/100","href":null,"code":true}]}]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null},"metadata_groups":[{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.issued","label":"Date","values":["2014"]},{"key":"dc:type","label":"Dc Type","values":["info:eu-repo/semantics/doctoralThesis"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["hdl:915/100"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.other","label":"Dc Description Other","values":["Background: Anemia is a frequent complication after cardiopulmonary bypass surgery. Iron therapy has been variably employed by medical centres over the years. Objective: To test the clinical effectiveness of intravenous and oral iron supplementation in correcting anemia, and its impact on blood transfusion requirements, in patients undergoing cardiopulmonary bypass (CPB) surgery. Methods: A double-blind randomized placebo-controlled clinical trial with three parallel groups of patients. Group I (n=54): intravenous iron III-hydroxide sucrose complex, three doses of 100 mg /24 hours during pre- and postoperative hospitalization and 1 pill/24 h of oral placebo in the same period and during one month after discharge. Group II (n=53): oral ferrous fumarate iron 1 pill/24 hours pre- and postoperatively and during one month after discharge, and intravenous placebo while hospitalized. Group III (n=52): oral and intravenous placebo pre- and postoperatively, following the same protocol. Data were collected preoperatively, at theatre, at Intensive Care Unit admission, before hospital discharge and one month later. Results: 1) Baseline clinical and demographic characteristics and surgical procedures were similar in the three groups, 2) no inter-group differences were found in hemoglobin and hematocrit during the postoperative period, 3) the intravenous iron group showed higher serum ferritin levels at hospital discharge (1321±495 ng/mL; P<0.001) and one month later (610±387;P< 0.001) compared with the other groups, and 4) we did not observe statistical differences in blood transfusion requirements between the three groups. Conclusion: The use of intravenous or oral iron supplementation proved ineffective at correcting anemia after CPB and did not reduce blood transfusion requirements."]},{"key":"dc:title","label":"Title","values":["Análisis de dos esquemas de tratamiento con hierro oral e intravenoso en cirugía cardiaca : ensayo clínico en fase IV, randomizado, doble ciego y doble enmascarado"]}]}],"canonical_facts":{"dc:date.issued":["2014"],"dc:description.other":["Background: Anemia is a frequent complication after cardiopulmonary bypass surgery. Iron therapy has been variably employed by medical centres over the years. Objective: To test the clinical effectiveness of intravenous and oral iron supplementation in correcting anemia, and its impact on blood transfusion requirements, in patients undergoing cardiopulmonary bypass (CPB) surgery. Methods: A double-blind randomized placebo-controlled clinical trial with three parallel groups of patients. Group I (n=54): intravenous iron III-hydroxide sucrose complex, three doses of 100 mg /24 hours during pre- and postoperative hospitalization and 1 pill/24 h of oral placebo in the same period and during one month after discharge. Group II (n=53): oral ferrous fumarate iron 1 pill/24 hours pre- and postoperatively and during one month after discharge, and intravenous placebo while hospitalized. Group III (n=52): oral and intravenous placebo pre- and postoperatively, following the same protocol. Data were collected preoperatively, at theatre, at Intensive Care Unit admission, before hospital discharge and one month later. Results: 1) Baseline clinical and demographic characteristics and surgical procedures were similar in the three groups, 2) no inter-group differences were found in hemoglobin and hematocrit during the postoperative period, 3) the intravenous iron group showed higher serum ferritin levels at hospital discharge (1321±495 ng/mL; P<0.001) and one month later (610±387;P< 0.001) compared with the other groups, and 4) we did not observe statistical differences in blood transfusion requirements between the three groups. Conclusion: The use of intravenous or oral iron supplementation proved ineffective at correcting anemia after CPB and did not reduce blood transfusion requirements."],"dc:identifier":["hdl:915/100"],"dc:title":["Análisis de dos esquemas de tratamiento con hierro oral e intravenoso en cirugía cardiaca : ensayo clínico en fase IV, randomizado, doble ciego y doble enmascarado"],"dc:type":["info:eu-repo/semantics/doctoralThesis"]},"updated_at":"2026-07-24T05:12:21Z"}